This is an exploratory study to evaluate endpoints used to characterize participants with and without meibomian gland dysfunction (MGD) and will evaluate the correlation between signs and symptoms of MGD. No investigational drug will be administered in this study.
Study Type
OBSERVATIONAL
Enrollment
75
Meibum expression as per protocol. No investigational drug is administered in this study.
Unnamed facility
Houston, Texas, United States
Unnamed facility
London, United Kingdom
Meibum Quality Score in the Study Eye as Assessed by the Investigator Using a 4-Point Scale
Time frame: Day 22
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.